Drug Profile
HepXia gene therapy - Oxford Biomedica
Latest Information Update: 13 Aug 2003
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 13 Aug 2003 Discontinued - Preclinical for Liver cancer in USA (Transurethral)
- 07 Jan 2002 No-Development-Reported for Liver cancer in USA (Transurethral)
- 22 Apr 1998 Preclinical development for Liver cancer in USA (Transurethral)